1-3 of 3
Anne-Marie Duliege, MDMS
Close
Sort by
Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1069.
https://doi.org/10.1182/blood-2019-126473
Published: 2019
Journal Articles

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Anne-Marie Duliege, MDMS, Donald M. Arnold, MD MSc, FRCPC, Ralph Boccia, MD, Michael Boxer, MD, Nichola Cooper, MRCP, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Darla K Liles, MD, Michelle Sholzberg, MDM, MSc, FRCPC, Hany Zayed, PhD, Sandra Tong, MD, James B. Bussel, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 736.
https://doi.org/10.1182/blood-2018-99-110482
Published: 2018
Journal Articles

Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results

James B. Bussel, MD, Donald M Arnold, MD, Nichola Cooper, MA, MD MRCP, FRCPath, Alhossain A Khalafallah, MD, Michael Boxer, MD, Darla Liles, MD, Waleed Ghanima, MD PhD, Keith McCrae, MD, Hany Zayed, Benoit Cadieux, PhD, Anne-Marie Duliege, MDMS
Journal: Blood
Blood (2017) 130 (Supplement 1): 16.
https://doi.org/10.1182/blood.V130.Suppl_1.16.16
Published: 2017